Informationen:
Fehler:
ID
13610
Beschreibung
Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00615784
Link
https://clinicaltrials.gov/show/NCT00615784
Stichworte
Versionen (1)
- 19.02.16 19.02.16 -
Rechteinhaber
CC BY-NC 3.0
Hochgeladen am
19. Februar 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Acute Myeloid Leukemia NCT00615784
Eligibility Acute Myeloid Leukemia NCT00615784
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Acute Myeloid Leukemia NCT00615784
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
age
Item
age >= 18 years
boolean
C0001779 (UMLS CUI [1])
aml
Item
confirmed diagnosis of aml as proven by bone marrow biopsy
boolean
C0023467 (UMLS CUI [1])
chemotherapy
Item
must have received prior induction therapy with conventional chemotherapy and/or mylotarg or otherwise not eligible for conventional chemotherapy
boolean
C0392920 (UMLS CUI [1])
C0876099 (UMLS CUI [2])
C0876099 (UMLS CUI [2])
ecog
Item
ecog performance status of 0-2
boolean
C1520224 (UMLS CUI [1])
recovery from toxicity
Item
recovered from toxicities of prior chemotherapy
boolean
C2004454 (UMLS CUI [1,1])
C0013221 (UMLS CUI [1,2])
C0013221 (UMLS CUI [1,2])
pancreatitis
Item
history of pancreatitis
boolean
C0030305 (UMLS CUI [1])
alcohol abuse
Item
active alcohol abuse
boolean
C0038586 (UMLS CUI [1])
bexarotene
Item
taken bexarotene in the past
boolean
C0765273 (UMLS CUI [1])
wbc
Item
wbc > 10,000/ul at time of enrollment
boolean
C0023508 (UMLS CUI [1])
cytotoxic therapy within the past 14 days other than hydrea, low dose cytarabine or low dose mylotarg
Item
cytotoxic therapy within the past 14 days other than hydrea, low dose cytarabine or low dose mylotarg
boolean
C0677881 (UMLS CUI [1])
C0591617 (UMLS CUI [2])
C0010711 (UMLS CUI [3])
C0876099 (UMLS CUI [4])
C0591617 (UMLS CUI [2])
C0010711 (UMLS CUI [3])
C0876099 (UMLS CUI [4])
organ disfunction
Item
significant organ disfunction: total bilirubin > 3x uln, ast or alt >3 x uln, creatinine > 3 mg/dl, on blood pressure supporting medications or mechanical ventilation
boolean
C0201976 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
C0201899 (UMLS CUI [4])
C0199470 (UMLS CUI [5])
C0005823 (UMLS CUI [6,1])
C0013227 (UMLS CUI [6,2])
C1278039 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
C0201899 (UMLS CUI [4])
C0199470 (UMLS CUI [5])
C0005823 (UMLS CUI [6,1])
C0013227 (UMLS CUI [6,2])
participation status
Item
active participant in any other investigational treatment study for aml
boolean
C2348568 (UMLS CUI [1])
life expectancy
Item
life expectancy of less than 1 month
boolean
C0023671 (UMLS CUI [1])
g-csf, gm-csf, aranesp, erythropoietin, or neumega
Item
use of blood growth factors (g-csf, gm-csf, aranesp, erythropoietin, or neumega) within 1 week prior to treatment initiation
boolean
C0079459 (UMLS CUI [1])
C0079460 (UMLS CUI [2])
C1134440 (UMLS CUI [3])
C0014822 (UMLS CUI [4])
C0537668 (UMLS CUI [5])
C0079460 (UMLS CUI [2])
C1134440 (UMLS CUI [3])
C0014822 (UMLS CUI [4])
C0537668 (UMLS CUI [5])
hyperlipidemia
Item
uncontrolled hyperlipidemia
boolean
C0020473 (UMLS CUI [1])
hiv
Item
known history of hiv
boolean
C0019682 (UMLS CUI [1])
cns involvement
Item
known active cns involvement with aml
boolean
C0449389 (UMLS CUI [1,1])
C0023467 (UMLS CUI [1,2])
C0023467 (UMLS CUI [1,2])
childbearing potential or active breast feeding
Item
women of childbearing potential or active breast feeding
boolean
C3831118 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])